Dianthus Therapeutics, Inc. $DNTH Shares Bought by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA grew its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 86.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 462,290 shares of the company’s stock after purchasing an additional 214,995 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Dianthus Therapeutics were worth $40,705,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. BlackRock Inc. acquired a new position in Dianthus Therapeutics during the 2nd quarter worth approximately $401,990,000. Wellington Management Group LLP increased its stake in Dianthus Therapeutics by 24.4% during the 2nd quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company’s stock worth $314,849,000 after buying an additional 634,099 shares during the period. Assenagon Asset Management S.A. increased its stake in Dianthus Therapeutics by 160.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 732,246 shares of the company’s stock worth $64,474,000 after buying an additional 451,597 shares during the period. Jennison Associates LLC acquired a new position in Dianthus Therapeutics in the 1st quarter worth $40,713,000. Finally, Spruce Street Capital LP lifted its holdings in Dianthus Therapeutics by 25.5% in the 1st quarter. Spruce Street Capital LP now owns 373,274 shares of the company’s stock worth $31,325,000 after buying an additional 75,837 shares in the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Citigroup began coverage on shares of Dianthus Therapeutics in a research report on Friday, September 4th. They issued a “buy” rating and a $156.00 price objective for the company. Raymond James Financial reaffirmed a “strong-buy” rating and set a $134.00 target price on shares of Dianthus Therapeutics in a research report on Thursday, November 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Thursday, October 15th. Roth Capital started coverage on Dianthus Therapeutics in a report on Tuesday, October 27th. They issued a “buy” rating and a $113.00 price target for the company. Finally, Wedbush raised their price objective on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Dianthus Therapeutics has an average rating of “Buy” and a consensus target price of $128.77.

Insider Transactions at Dianthus Therapeutics

In other news, EVP Simrat Randhawa sold 23,124 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $106.41, for a total value of $2,460,624.84. Following the completion of the sale, the executive vice president directly owned 4,000 shares in the company, valued at approximately $425,640. The trade was a 85.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Edward Carr sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $101.38, for a total value of $2,027,600.00. Following the sale, the chief accounting officer directly owned 20,000 shares in the company, valued at approximately $2,027,600. This represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 45,902 shares of company stock valued at $4,814,779. Insiders own 3.02% of the company’s stock.

Key Dianthus Therapeutics News

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its EPS estimates for 2026–2028, reflecting smaller projected losses, and reiterated a Buy rating with a $158 price target. The revised estimates could support investor optimism, though they are forecasts rather than company results. MarketBeat analyst estimates
• Positive Sentiment: A Zacks article cited analyst price targets implying 61.2% upside and noted that rising earnings estimates can be a positive signal, while also cautioning that price-target data has limited predictive value. Zacks article
• Neutral Sentiment: A report said short interest was zero shares as of November 10, despite describing it as a large increase. That inconsistency makes the figure difficult to interpret as a meaningful trading signal.
• Negative Sentiment: A Yahoo Finance article said DNTH may look stretched even as pipeline progress draws attention, which could temper enthusiasm after the stock’s strong run. Yahoo Finance article
• Negative Sentiment: HC Wainwright sharply cut its FY2029 EPS forecast from a small loss to a larger loss, and reduced its FY2030 estimate from $10.75 to $2.35 per share. Those longer-term revisions offset some of the improved nearer-term outlook. MarketBeat analyst estimates

Dianthus Therapeutics Trading Down 1.3%

Shares of NASDAQ:DNTH opened at $88.81 on Wednesday. The firm has a market cap of $5.00 billion, a PE ratio of -22.26 and a beta of 1.47. The company has a fifty day simple moving average of $89.39 and a 200 day simple moving average of $85.96. Dianthus Therapeutics, Inc. has a 12-month low of $34.29 and a 12-month high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.13. The firm had revenue of $1.21 million for the quarter, compared to the consensus estimate of $0.46 million. Dianthus Therapeutics had a negative net margin of 7,436.50% and a negative return on equity of 19.68%. As a group, equities research analysts forecast that Dianthus Therapeutics, Inc. will post -3.55 EPS for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company’s research focuses on selectively targeting complement activity that contributes to disease. Dianthus became a publicly traded company in 2023 through a merger with Magenta Therapeutics. Its clinical development activities are intended to support potential use across patient populations, though the company has not established a commercial geographic footprint.